JP2016536004A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536004A5 JP2016536004A5 JP2016542081A JP2016542081A JP2016536004A5 JP 2016536004 A5 JP2016536004 A5 JP 2016536004A5 JP 2016542081 A JP2016542081 A JP 2016542081A JP 2016542081 A JP2016542081 A JP 2016542081A JP 2016536004 A5 JP2016536004 A5 JP 2016536004A5
- Authority
- JP
- Japan
- Prior art keywords
- recurrence
- risk
- therapy
- subject
- years
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 59
- 238000002626 targeted therapy Methods 0.000 claims description 23
- 239000003886 aromatase inhibitor Substances 0.000 claims description 22
- 238000009261 endocrine therapy Methods 0.000 claims description 22
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 20
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 19
- 206010006187 Breast cancer Diseases 0.000 claims description 15
- 208000026310 Breast neoplasm Diseases 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 12
- 102000011682 Centromere Protein A Human genes 0.000 claims description 9
- 108010076303 Centromere Protein A Proteins 0.000 claims description 9
- 101001019600 Homo sapiens Interleukin-17 receptor B Proteins 0.000 claims description 9
- 101001096541 Homo sapiens Rac GTPase-activating protein 1 Proteins 0.000 claims description 9
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 claims description 9
- 101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 claims description 9
- 102100035014 Interleukin-17 receptor B Human genes 0.000 claims description 9
- 102100037414 Rac GTPase-activating protein 1 Human genes 0.000 claims description 9
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 claims description 9
- 102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 238000009098 adjuvant therapy Methods 0.000 claims description 6
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- -1 Bub1B Proteins 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 238000011221 initial treatment Methods 0.000 claims description 3
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 claims description 2
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 claims description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 claims description 2
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 238000000513 principal component analysis Methods 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 229940046844 aromatase inhibitors Drugs 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876757P | 2013-09-11 | 2013-09-11 | |
| US61/876,757 | 2013-09-11 | ||
| PCT/US2014/055041 WO2015038682A1 (en) | 2013-09-11 | 2014-09-10 | Predicting breast cancer recurrence |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016536004A JP2016536004A (ja) | 2016-11-24 |
| JP2016536004A5 true JP2016536004A5 (enExample) | 2017-10-19 |
Family
ID=52666241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542081A Pending JP2016536004A (ja) | 2013-09-11 | 2014-09-10 | 乳癌再発の予測 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150203921A1 (enExample) |
| EP (1) | EP3044335B1 (enExample) |
| JP (1) | JP2016536004A (enExample) |
| CN (1) | CN105722998A (enExample) |
| BR (1) | BR112016005225B1 (enExample) |
| CA (1) | CA2923606A1 (enExample) |
| ES (1) | ES2829912T3 (enExample) |
| IL (2) | IL244554B (enExample) |
| MX (2) | MX2016002938A (enExample) |
| WO (1) | WO2015038682A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030198972A1 (en) | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
| US9856533B2 (en) | 2003-09-19 | 2018-01-02 | Biotheranostics, Inc. | Predicting breast cancer treatment outcome |
| WO2012079059A2 (en) | 2010-12-09 | 2012-06-14 | Biotheranostics, Inc. | Post-treatment breast cancer prognosis |
| MX2018005867A (es) | 2015-11-13 | 2018-09-21 | Biotheranostics Inc | Integracion de las caracteristicas tumorales con el indice de cancer de mama. |
| MX2021001857A (es) * | 2018-08-17 | 2021-10-13 | Genentech Inc Star | Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama. |
| CN112646890B (zh) * | 2020-12-29 | 2024-08-16 | 郑鸿钧 | 用于预测早期乳腺癌远处复发风险的多基因检测引物 |
| EP4594533A1 (en) * | 2022-09-30 | 2025-08-06 | Biotheranostics, Inc. | Biomarker assay to select breast cancer therapy |
| CN117476246B (zh) * | 2023-12-25 | 2024-04-19 | 福建大数据一级开发有限公司 | 基于多类型复发事件的患者生存分析方法、介质及装置 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
| CA2350502C (en) | 1998-11-13 | 2009-01-27 | Pro Duct Health, Inc. | Devices and methods to identify ductal orifices during nipple aspiration |
| US6794141B2 (en) | 2000-12-22 | 2004-09-21 | Arcturus Bioscience, Inc. | Nucleic acid amplification |
| US20030198972A1 (en) | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
| AU2004274973A1 (en) | 2003-09-19 | 2005-03-31 | Aviaradx, Inc. | Predicting breast cancer treatment outcome |
| US9856533B2 (en) | 2003-09-19 | 2018-01-02 | Biotheranostics, Inc. | Predicting breast cancer treatment outcome |
| US7504214B2 (en) | 2003-09-19 | 2009-03-17 | Biotheranostics, Inc. | Predicting outcome with tamoxifen in breast cancer |
| CA2698569A1 (en) * | 2007-09-06 | 2009-09-03 | Mark G. Erlander | Tumor grading and cancer prognosis |
| CN105821125A (zh) * | 2010-03-31 | 2016-08-03 | 斯维丹诊断有限责任公司 | 用于内分泌治疗下的乳腺癌复发预测的方法 |
| WO2012079059A2 (en) * | 2010-12-09 | 2012-06-14 | Biotheranostics, Inc. | Post-treatment breast cancer prognosis |
| CA2854805C (en) * | 2011-11-08 | 2021-04-27 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
-
2014
- 2014-09-10 US US14/483,108 patent/US20150203921A1/en not_active Abandoned
- 2014-09-10 WO PCT/US2014/055041 patent/WO2015038682A1/en not_active Ceased
- 2014-09-10 MX MX2016002938A patent/MX2016002938A/es unknown
- 2014-09-10 CN CN201480061817.8A patent/CN105722998A/zh active Pending
- 2014-09-10 ES ES14843312T patent/ES2829912T3/es active Active
- 2014-09-10 JP JP2016542081A patent/JP2016536004A/ja active Pending
- 2014-09-10 BR BR112016005225-0A patent/BR112016005225B1/pt active IP Right Grant
- 2014-09-10 EP EP14843312.1A patent/EP3044335B1/en active Active
- 2014-09-10 CA CA2923606A patent/CA2923606A1/en not_active Abandoned
-
2016
- 2016-03-04 MX MX2021002014A patent/MX2021002014A/es unknown
- 2016-03-10 IL IL244554A patent/IL244554B/en active IP Right Grant
-
2020
- 2020-08-05 IL IL276505A patent/IL276505B/en unknown
-
2021
- 2021-10-28 US US17/513,640 patent/US20220186317A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536004A5 (enExample) | ||
| KR102648633B1 (ko) | 암 예후 예측용 조성물 | |
| Marcuello et al. | Circulating biomarkers for early detection and clinical management of colorectal cancer | |
| Amaria et al. | Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial | |
| Persiani et al. | Log odds of positive lymph nodes in colon cancer: A meaningful ratio‐based lymph node classification system | |
| Mian et al. | MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome | |
| Wang et al. | Identification and verification of an immune-related lncRNA signature for predicting the prognosis of patients with bladder cancer | |
| Griffith et al. | Salivary duct carcinoma and the concept of early carcinoma ex pleomorphic adenoma | |
| Gupta et al. | Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review | |
| JP2010538609A5 (enExample) | ||
| CN105319364B (zh) | 用于预测小肝癌复发的联合诊断标记 | |
| JP2016500512A (ja) | 肝臓サンプルの分類ならびに限局性結節性異形成、肝細胞腺腫および肝細胞癌の診断のための新規方法 | |
| Demirtaş et al. | Can Neutrophil‐Lymphocyte Ratio and Lymph Node Density Be Used as Prognostic Factors in Patients Undergoing Radical Cystectomy? | |
| JP2016521979A5 (enExample) | ||
| Mesquita et al. | Molecular analysis of single circulating tumour cells following long‐term storage of clinical samples | |
| WO2018097614A2 (ko) | 유방암 환자의 화학치료 유용성 예측 방법 | |
| WO2014158696A9 (en) | Methods for predicting risk of metastasis in cutaneous melanoma | |
| JP2020523991A (ja) | Ｐｒａｅｇｎａｎｔ転移性乳癌コホートにおける不良アウトカムの予後指標因子 | |
| CN112575085B (zh) | 用于肾上腺皮质癌预后的基因表达谱 | |
| Sales et al. | Mirna21 expression in the breast cancer tumor tissue is independent of neoadjuvant chemotherapy | |
| Moghaddam et al. | Comparison of three mathematical models for predicting the risk of additional axillary nodal metastases after positive sentinel lymph node biopsy in early breast cancer | |
| Prendeville et al. | Lymph node staging in prostate cancer: perspective for the pathologist | |
| Yu et al. | IMP‐3 expression in melanocytic lesions | |
| CN104975082A (zh) | 一组用于评估肺癌预后的基因及其应用 | |
| Altintas et al. | Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS) |